ID   GAK
AC   CVCL_1225
DR   CLO; CLO_0037126
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472868
DR   cancercelllines; CVCL_1225
DR   Cell_Model_Passport; SIDM00543
DR   CGH-DB; 9290-4
DR   ChEMBL-Cells; CHEMBL3308154
DR   ChEMBL-Targets; CHEMBL2366301
DR   Cosmic; 905204
DR   Cosmic; 910932
DR   Cosmic; 1995410
DR   Cosmic-CLP; 910932
DR   DepMap; ACH-002120
DR   EGA; EGAS00001000978
DR   GDSC; 910932
DR   GEO; GSM1669803
DR   IARC_TP53; 21337
DR   JCRB; IFO50321
DR   JCRB; JCRB0180
DR   JCRB; FDSC0034
DR   LINCS_LDP; LCL-1272
DR   PharmacoDB; GAK_397_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1225
DR   Wikidata; Q54835424
RX   PubMed=6431036;
RX   PubMed=15467732;
RX   PubMed=20164919;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 72 hours (PubMed=6431036); ~55 hours (Note=Lot 07202012) (JCRB=IFO50321); ~32 hours (Note=Lot 02242012) (JCRB=JCRB0180).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (Cosmic-CLP=910932; DepMap=ACH-002120).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=77.89%; East Asian, South=22.1%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0034; true.
CC   Derived from site: Metastatic; Inguinal lymph node; UBERON=UBERON_0001542.
ST   Source(s): Cosmic-CLP=910932; JCRB=IFO50321; JCRB=JCRB0180; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 9,13
ST   D16S539: 12
ST   D18S51: 13
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 18,20
ST   D3S1358: 16
ST   D5S818: 10
ST   D7S820: 11
ST   D8S1179: 10,11
ST   FGA: 24
ST   Penta D: 9,11
ST   Penta E: 9,10
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 15,18
DI   NCIt; C40329; Vulvar melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   86Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 36
//
RX   PubMed=6431036;
RA   Nozawa S., Ohta H., Tsukazaki K., Udagawa Y., Kurihara S., Kano S.;
RT   "A newly established melanoma cell line (GAK) with 5-S-cysteinyldopa
RT   phenotype.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 36:883-892(1984).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//